Mechanism of Action of Transcranial Magnetic Stimulation
1 other identifier
interventional
54
1 country
1
Brief Summary
This is an observational neuroimaging study assessing the effects of TMS on the brains of patients with unipolar depression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable major-depressive-disorder
Started Nov 2011
Longer than P75 for not_applicable major-depressive-disorder
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2011
CompletedFirst Submitted
Initial submission to the registry
February 18, 2020
CompletedFirst Posted
Study publicly available on registry
February 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
December 12, 2025
December 1, 2025
14.6 years
February 18, 2020
December 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in Functional Connectivity of Key Nodes in Depression
Measured by Magnetic Resonance Imaging
Through Treatment Completion, Average of 6 Weeks
Study Arms (1)
Unipolar Depression
OTHERPatients diagnosed with unipolar depression.
Interventions
Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
Eligibility Criteria
You may qualify if:
- Males and females between the ages of 18-80
- DSM-IV diagnosis of Depressive Episode
- Patients requiring TMS treatment as part of their psychiatric care
You may not qualify if:
- Comorbid DSM-IV primary diagnoses of schizoaffective disorder, schizophrenia or dementia.
- Substance use disorder (abuse or dependence) with active use within the last 3 months
- Severe or unstable medical illness.
- MRI contraindications as determined by MGH department of radiology.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Massachusetts General Hospital
Boston, Massachusetts, 02129, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joan Camprodon, MD, PhD, MPH
Massachusetts General Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of Division of Neuropsychiatry, Director of TMS Clinic, Director of Lab for Neuropsychiatry and Neuromodulation
Study Record Dates
First Submitted
February 18, 2020
First Posted
February 20, 2020
Study Start
November 1, 2011
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
December 12, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share